CDO1与CELF4甲基化检测是子宫内膜癌的主要预测指标:跨绝经状态队列分析
这项前瞻性队列研究纳入573例拟行宫腔镜诊断的女性,评估宫颈刮取物CDO1与CELF4甲基化检测(CISENDO)对子宫内膜癌的诊断和分诊价值。结果显示该检测在绝经前和绝经后女性中均有高灵敏度、特异度和AUC,且是多变量分析中最强的独立预测因子。
要点
- CISENDO检测在绝经前女性中灵敏度89.7%、特异度93.0%、AUC 0.91。
- 绝经后女性中灵敏度91.7%、特异度91.8%、AUC 0.92。
- 联合子宫内膜厚度可提高灵敏度但降低特异度。
核心结论
- 无创CDO1与CELF4甲基化检测对子宫内膜癌具有高诊断准确性,是有前景的无创诊断和分诊工具。
研究设计与样本
- 前瞻性队列研究,纳入573例拟行诊断性宫腔镜的参与者,包括524例非子宫内膜癌、41例子宫内膜癌和8例子宫内膜上皮内瘤变病例。
主要发现
- 绝经前子宫内膜癌患者中CISENDO检测灵敏度89.7%、特异度93.0%、AUC 0.91。
- 绝经后子宫内膜癌患者中灵敏度91.7%、特异度91.8%、AUC 0.92。
- CISENDO联合子宫内膜厚度使灵敏度提高至绝经前96.6%、绝经后100%,但特异度降低。
- 55.2%的绝经前子宫内膜癌病例子宫内膜厚度<11 mm但CISENDO阳性。
- 52.7%的子宫内膜厚度≥5 mm的绝经后非子宫内膜癌女性CISENDO阴性。
关键数值与推荐
- 多变量分析中CISENDO检测是子宫内膜癌最强的独立预测因子,绝经前调整OR=103.9,绝经后调整OR=118.0,P<0.001。
临床怎么用
- CISENDO检测可用于子宫内膜癌的无创诊断和分诊,尤其适用于高风险女性和早期疾病患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The rising global incidence of endometrial cancer (EC) necessitates the development of non-invasive, accurate detection methods to improve early diagnosis and optimize referrals for hysteroscopy. This study evaluated the diagnostic and triage value of a CDO1 and CELF4 methylation (CISENDO) assay using cervical scrapings for EC detection, and its independent association with EC across menopausal statuses. METHODS: In this prospective cohort study, 573 participants for diagnostic hysteroscopy were enrolled, including 524 non-EC, 41 EC, and 8 endometrial intraepithelial neoplasia (EIN) cases. The diagnostic performance of the CISENDO assay, alone and combined with endometrial thickness (ET) measured by transvaginal ultrasound (TVS), was assessed. Analyses were stratified by menopausal status. Univariate and multivariate logistic regression identified independent EC predictors. RESULTS: The CISENDO assay demonstrated high discriminatory performance. In premenopausal women with EC, sensitivity was 89.7%, specificity 93.0%, and AUC 0.91. In postmenopausal women with EC, sensitivity was 91.7%, specificity 91.8%, and AUC 0.92. Combining CISENDO with ET increased sensitivity (96.6% premenopausal; 100% postmenopausal) but reduced specificity. Notably, 55.2% of premenopausal EC cases had ET <11 mm but were CISENDO-positive, while 52.7% of non-EC postmenopausal women with ET ≥5 mm were CISENDO-negative. Multivariable analysis identified the CISENDO assay as the strongest independent predictor of EC (adjusted OR = 103.9 in premenopausal and 118.0 in postmenopausal women; P < 0.001). CONCLUSIONS: The non-invasive CDO1 and CELF4 methylation assay demonstrates high diagnostic accuracy for EC and represents a promising tool for non-invasive diagnosis and triage, particularly in women at high risk for EC and those with early-stage disease.
引用
- Wang X, Zheng L, Zhu G, et al. CDO1 and CELF4 methylation assay as the dominant predictor of endometrial cancer: A cohort analysis across pre- and post-menopausal cohorts. Gynecol Oncol. 2026. PMID: 41691764. doi:10.1016/j.ygyno.2026.01.776
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。